Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Verteporfin and Senescence: A Careful Evidence Map
2026-10-05
Verteporfin, also known as CL 318952, is best understood through an evidence map that separates photodynamic cytotoxicity, autophagy modulation, and true senolytic selectivity. This article connects its reported biology with machine-learning-enabled senolytic discovery while clarifying what the evidence does—and does not—support.
Verteporfin (CL 318952): Mechanism and Evidence
2026-10-04
Verteporfin, also known as CL 318952, is a photosensitizer used in photodynamic therapy for selected ocular neovascularization. Evidence also supports a separate, light-independent interaction with p62, but preclinical cell findings should not be treated as universal potency thresholds or clinical efficacy.
iRhom2 in Olfaction: Receptor Regulation and Adaptation
2026-10-03
Azzopardi and colleagues identify iRhom2 as a distinctive regulator in mouse olfactory sensory neurons and link its expression to odor-dependent transcriptional adaptation. The study connects iRhom2/ADAM17 signaling with olfactory receptor regulation while highlighting important limits on translating results from knockout mice and heterologous cell systems to native olfactory tissue.
CD38 CAR Binder Structures and Affinity Tuning
2026-10-02
Cheng et al. define how the CD38-targeting binders RP02 and 028 engage different antigen surfaces, linking epitope geometry to enzymatic inhibition and CAR-T behavior. The study further shows that the affinity-attenuated 028R103G variant can reduce CAR-T fratricide while retaining cytotoxicity against CD38-positive tumor cells, providing a structure-guided framework for optimizing binder performance.
A 83-01: Selective ALK-5 Inhibitor Guide
2026-10-01
A 83-01 is a selective ALK-5 inhibitor that suppresses TGF-β/Smad signaling and supports epithelial-mesenchymal transition (EMT) research. Product-reported activity includes an approximately 12 nM IC50 and 68% inhibition of ALK-5-induced reporter activity at 1 μM in Mv1LuR4-2 cells.
Imipramine: A Smarter Autophagy Assay Strategy
2026-10-01
Imipramine is a tricyclic antidepressant with applications spanning glioma cell autophagy research, apoptosis assays, and neurobiology. This article develops a decision framework that connects the compound’s research profile with ceramide-driven autophagy findings while clearly separating evidence from testable hypotheses.
SB 431542 Workflow for ALK5 Inhibition
2026-09-30
SB 431542 provides a practical way to test ALK5-dependent TGF-β responses in cancer, immune, and stem/progenitor-cell assays. This workflow combines mechanism-based controls with the long-term myogenic engraftment framework reported in a 2025 human PSC study, while emphasizing dose selection, timing, and interpretation limits.
N4-Acetylcytidine: RNA Modification Workflows
2026-09-30
N4-Acetylcytidine supports controlled studies of free ac4C metabolism, post-transcriptional RNA modification, and enzyme substrate specificity. This guide separates RNA-embedded biology from free acetylated cytidine assays, with practical preparation, controls, troubleshooting, and structure-guided applications.
Human iPSC Sensory Neurons Model HSV-1 Latency
2026-09-29
Oh et al. developed a scalable human induced pluripotent stem cell system that rapidly produces functional sensory neurons and supports experimentally defined HSV-1 latency and reactivation. The model combines neuronal physiology with virological, transcriptional, and chromatin-based validation, offering a human-relevant platform for studying neuron-intrinsic mechanisms and testing latency-directed interventions.
TBXA2R–ERM Signaling in TNBC Metastasis
2026-09-29
The reference study identifies TBXA2R as a GPCR that activates ezrin, radixin, and moesin through Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK. This signaling axis links receptor activity to triple-negative breast cancer cell motility, invasion, and metastatic colonization, establishing ERM function as a mechanistic requirement rather than a passive correlate.
Necrosulfonamide Workflows for MLKL Research
2026-09-28
Necrosulfonamide provides a selective way to test whether membrane-disruptive necroptosis, rather than apoptosis, drives a radiation response. This practical guide connects NSA handling and assay controls with carbon-ion cancer research, emphasizing interpretable workflows and troubleshooting.
A 83-01 ALK-5 Inhibitor for Kidney Fibrosis
2026-09-28
Use A 83-01 to test whether ALK-5-dependent TGF-β signaling contributes to fibroblast activation—not as a stand-in for Spp1 perturbation. This kidney-fibrosis workflow pairs carefully controlled inhibitor dosing with early Smad readouts and later myofibroblast markers, while flagging selectivity and vehicle controls that matter for interpretation.
AT-406 in TNBC: Reading Cell Death Beyond Apoptosis
2026-09-27
AT-406 (SM-406) can help researchers interrogate how IAP inhibition reshapes cell-death responses in cancer models. This article examines recent TNBC findings and translates them into a practical framework for distinguishing apoptosis from necroptosis-like and autophagy-associated signals.
Risedronate Sodium: Practical Bone and Lung Workflows
2026-09-26
Turn Risedronate Sodium’s FPPS inhibition into practical workflows for osteoclast and pulmonary-delivery studies, with dose-screening, formulation, and troubleshooting guidance. A lung-targeted Risedronate/vitamin D₃ study offers a useful nanoparticle benchmark while also clarifying what remains preclinical.
DEBIO 1143 in Murine TNBC: Cell-Death Mechanisms
2026-09-25
This study combines cell-based assays with molecular docking and 1-μs molecular-dynamics simulations to examine DEBIO 1143 in murine breast cancer models. Its findings link cIAP1 depletion with cytotoxicity and increased autophagy-associated and necroptosis-like responses, while cautioning that these changes do not establish direct drug binding to the measured downstream mediators.
8675 records 6/579 page Previous Next First page 上5页 678910 下5页 Last page